-
Lancet Haematol: Zebratinib is expected to be a new option for patients with B-cell malignancies who were previously intolerant to BTK
Time of Update: 2023-01-04
This is an ongoing, multicenter, open-label, single-arm Phase 2 clinical trial to evaluate whether zebratinib can prolong treatment in previously treated patients with B-cell malignancies by minimizing treatment-related toxicity and discontinuation.
-
J Clin Oncol: salvage radiotherapy + enzalutamide for high-risk prostate cancer with PSA recurrence after radical surgery
Time of Update: 2023-01-04
The aim of this study was to explore whether enzalutamide combined with salvage radiotherapy (SRT) prolongs survival without prostate-specific antigen (PSA) progression (FFPP) in patients with recurrent prostate cancer after radical prostatectomy (RP).
-
J Clin Oncol: Long-term prognosis of Tisagenlecleucel in the treatment of relapsed/refractory acute lymphoblastic leukemia
Time of Update: 2023-01-04
In the Phase 2 ELIANA trial, the first analysis, Tisagenlecleucel induced high remission rates (81%) in children and young patients with R/R B-ALL, and 59% of responding patients remained relapse-free at 12 months.
-
Cancer cells "carry weight", Nature research shows that the higher the extracellular viscosity, the faster the tumor spreads
Time of Update: 2023-01-04
Cells trained with high extracellular viscosity form "memories" that exhibit enhanced migration, extravasation, and lung colonizationTaken together, this Nature study sheds light on how cells sense and respond to highly viscous extracellular fluid and demonstrates that extracellular viscosity is a key physiological feature that has an important impact on the spread and migration of cancer cells.
-
With cancer death rates down 32% and more than 18 million survivors, what is cancer treatment right in the United States?
Time of Update: 2023-01-04
American doctors treat each cancer patient as an individual and conduct multidisciplinary consultation, including members of surgery, medical oncology, radiotherapy, pathology, and imaging; Develop a comprehensive individualized treatment plan to avoid blind, inefficient, and even wrong treatment.
-
Prostate: Is the detrusor ring of the bladder related to lower urinary tract symptoms caused by benign prostatic hyperplasia?
Time of Update: 2023-01-04
dilation of DMR around the bladder outlet is a new anatomical factor and is independently associated with moderate and severe LUTS/BPHOriginal source:Original source:Kiran R Nandalur， David Walker， Hong Ye et al.
-
Eur Urol Focus: Interim oncological efficacy and patient-reported outcomes after local high-intensity focused ultrasound therapy for prostate cancer
Time of Update: 2023-01-04
Multiparametric magnetic resonance imaging (mpMRI)/transrectal ultrasound (TRUS) fusion guided high-intensity focused ultrasound (HIFU) therapy is a local treatment for local prostate cancer (PCa) seen by MRI.
Nov 2022 Multiparametric magnetic resonance imaging (mpMRI)/transrectal ultrasound (TRUS) fusion guided high-intensity focused ultrasound (HIFU) therapy is a local treatment for local prostate cancer (PCa) seen by MRI.
-
J Clin Oncol: Long-term prognosis of daratumumab in combination with bortezomib and dexamethasone in multiple myeloma
Time of Update: 2023-01-04
The trial was a multicenter, randomized, open-label, Phase 3 study enrolling patients with relapsed or refractory multiple myeloma who had previously received ≥ 1st line therapy and were randomized to Vd (up to 8 courses) or Vd + daratumumab (D-Vd) (treatment until disease progression).
-
European Radiology: Relationship between histopathological components of mixed hepatocellular carcinoma-cholangiocarcinoma and MRI features and prognosis
Time of Update: 2023-01-04
Mixed liver carcinoma-cholangiocarcinoma (cHCC-CCA) is a primary liver cancer defined by well-defined components of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). The 2019 WHO classific
-
The final blow of dying cancer cells: the release of ATP to send a message to help neighboring cancer cells develop resistance
Time of Update: 2023-01-04
On November 16, 2022, researchers from the Georg-Speyer-Haus Institute for Tumor Biology and Experimental Therapeutics in Germany published a research paper in Nature entitled: Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation。 The study found that when chemotherapy drugs cause colorectal cancer cells to die, they release ATP (which acts as the cell's energy currency and also as a messenger substance).
-
Cell Stem Cell: Targets CD47, which not only treats cancer, but also restores muscle strength and fights aging
Time of Update: 2023-01-04
The study utilized single-cell mass spectrometry flow cytometry to identify high CD47 expression as a hallmark of dysfunctional muscle stem cells, and further determined that platelet-reactive protein-1 (THBS1) binds to CD47 on the surface of muscle stem cells, thereby inhibiting muscle stem cell activity.
-
System Introduction Radiotherapy and improvement techniques in clinical application
Time of Update: 2023-01-04
," which provides clinicians with an overview describingthe process of ART, in particular MRgART。 This review focuses on the concept of adaptive RT (ART) and, more specifically, magnetic resonance (MR)-guided ART (MRgART), which is achieved by integrating an MR imaging (MRI) scanner into a linear accelerator (linacs) for transmitting radiation.
-
Deubiquitinase: A New Opportunity for Small Molecule Drug Discovery
Time of Update: 2023-01-04
Figure 1, Ubiquitination/Deubiquitination SystemThere are about 100 different deubiquitinating enzymes in the human body, which can be divided into ubiquitin-specific proteases (USPs), ubiquitin-specific proteases (USPs), ubiquitin carboxyl-terminal hydrolases (UCHs), ovarian tumor proteases (OTUs), Machado-Joseph disease protein domain proteases (MJDs), JAMM/MPN region-associated metallopeptidases (JAMMs), zinc-containing ubiquitin peptidases 1 ( ZUP1) and 7 families including the new DUB family (MINDYs) in which motif interacts with ubiquitins.
-
Cancer Res: A new method for accurate and comprehensive detection of cancer gene fusion events based on long-read sequencing: FusionSeeker
Time of Update: 2023-01-04
Recently, a research team at the University of Alabama at Birmingham proposed a gene fusion detection tool, FusionSeeker, which can accurately and comprehensively identify gene fusion events in long-reading cancer transcriptome sequencing data and reconstruct accurate fusion transcripts from original reads.
-
NCCN Antiemetic Clinical Practice Guidelines 2022.2 (Chinese)
Time of Update: 2023-01-04
c. For some drugs with low risk of vomiting, factors related to dosing regimens (especially continuous administration) and clinical experience suggest that routine pretreatment is not required.
-
Steady, accurate, ruthless! Head and neck cancer treatment ushered in a new spring~
Time of Update: 2023-01-04
Although proton is radiotherapy, it is "perfect" in the treatment of head and neck cancers - repelling tumor tissue while reducing complications and side effects.
Although proton is radiotherapy, it is "perfect" in the treatment of head and neck cancers - repelling tumor tissue while reducing complications and side effects.
-
Blood: Ph+ALL patients do not benefit from allogeneic hematopoietic cell transplantation!
Time of Update: 2023-01-04
Overall, the results of this retrospective study suggest that adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who achieve a complete molecular response within 90 days of initiating treatment do not derive a survival benefit from allo-HCT at first complete response.
-
Lancet Haematol: Panatinib in combination with bonatumab for Ph-positive acute lymphoblastic leukemia
Time of Update: 2023-01-04
This is a single-center, single-arm Phase 2 clinical trial enrolling patients aged 18 years of age with newly diagnosed or relapsed/refractory Ph-positive acute lymphoblastic leukemia or chronic myeloid leukemia, and requires ECOG performance status ≤ 2 points, total bilirubin not exceeding twice the upper limit of normal (≤ 2.
-
Blood: Single-cell omics reveals multilayered molecular mechanisms of CLL acquired venetox resistance
Time of Update: 2023-01-04
To fully understand the mechanisms of clinical resistance in VEN, the researchers combined single-cell short-read and long-read RNA sequencing to reveal the previously unrecognized scale of genetic and epigenetic changes supporting acquired VEN resistance.
-
CRISPR gene editing faces a "pedigree conundrum": the genetic diversity of Africans leads to off-target effects
Time of Update: 2023-01-04
The study shows that because the reference genome used in the gRNA design process for CRISPR gene editing often does not consider lineage, important cancer target genes in people of African ancestry may be missed in cancer gene research.
